25 completed, 9 recruiting, 6 unknown, 5 active not recruiting. 32 Phase 2, 12 Phase 1, 7 Phase 3, 4 Early Phase 1, 2 Not applicable.
Follow Sarcoma, Alveolar Soft Part: new trials by email Literature Review of Sarcoma, Alveolar Soft Part trials Research Report on Sarcoma, Alveolar Soft Part
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours Fludarabine, Cyclophosphamide, GCAR1 - Alveolar Soft Part Sarcoma, Renal Cell Carcinoma | Phase 1 | Recruiting | Canadian Cancer Trials Group | 30 | 2026-08-30 | 2026-10-16 |
| Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma Benmelstobart injection combined with Anlotinib hydrochloride capsule - Alveolar Soft Part Sarcoma | Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 33 | 2026-04-02 | 2026-04-23 |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University of Florida | 27 | 2026-02-11 | 2026-06-30 |
| A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing Atezolizumab - Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2025-11-04 | 2026-10-16 |
| A Study to Determine the Safety and Effectiveness of the Investigational Cellular Therapy GCAR1 in a Patient With Alveolar Soft Part Sarcoma GCAR1 - Alveolar Soft Part Sarcoma (ASPS), Sarcoma | Early Phase 1 | Active not recruiting | University of Calgary | 1 | 2025-08-21 | 2026-08-04 |
| CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma GCAR1 - Sarcoma, Alveolar Soft Part Sarcoma (ASPS) | Early Phase 1 | Active not recruiting | University of Calgary | 1 | 2025-01-30 | 2025-04-10 |
| Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma Biopsy, Chest Computed Tomography, Chest Radiography - Adult Pleomorphic Rhabdomyosarcoma, AJCC Grade 2 Sarcoma | Not applicable | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 1582 | 2025-01-28 | 2024-07-30 |
| GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02) GCAR1 - Alveolar Soft Part Sarcoma | Early Phase 1 | Active not recruiting | AHS Cancer Control Alberta | 1 | 2024-02-01 | 2026-03-23 |
| GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma GCAR1 - Alveolar Soft Part Sarcoma | Early Phase 1 | Completed | AHS Cancer Control Alberta | 1 | 2023-09-06 | 2025-07-23 |
| Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial Atezolizumab, Biopsy Procedure, Biospecimen Collection - Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 27 | 2022-08-29 | 2026-10-02 |
| AB122 Platform Study AB122, TAS-116, TAS-120 - Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Taiho Pharmaceutical Co., Ltd. | 917 | 2021-06-01 | 2026-08-05 |
| Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group Patient with Soft Tissue Sarcoma - Soft Tissue Sarcoma, Clear Cell Sarcoma | Not applicable | Recruiting | Institut Claudius Regaud | 400 | 2021-04-26 | 2026-02-10 |
| Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Selinexor, Ixazomib - Liposarcoma, Malignant Peripheral Nerve Sheath Tumors | Phase 1 | Withdrawn | Matthew Ingham | 2020-11-01 | 2020-11-27 | |
| A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin - Sarcoma, Myxofibrosarcoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2020-04-01 | 2026-04-23 |
| Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226) GB226 - Alveolar Soft Part Sarcoma | Phase 2 | Unknown | Genor Biopharma Co., Ltd. | 35 | 2018-09-06 | 2021-03-03 |
| Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Hypofractionated radiotherapy, Hyperthermia - Sarcoma, Alveolar Soft Part Sarcoma | Phase 2 | Unknown | Maria Sklodowska-Curie National Research Institute of Oncology | 30 | 2018-06-01 | 2021-02-01 |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) AL3818, Dacarbazine, AL3818 or placebo - Alveolar Soft Part Sarcoma, Leiomyosarcoma | Phase 3 | Recruiting | Advenchen Laboratories, LLC | 325 | 2017-08-15 | 2026-02-25 |
| Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo], Epirubicin - Soft Tissue Sarcoma, Bone Sarcoma | Phase 1 / Phase 2 | Completed | Grupo Espanol de Investigacion en Sarcomas | 197 | 2017-05-31 | 2024-08-13 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Cabozantinib, Cabozantinib S-malate, Pharmacological Study - Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 109 | 2017-05-18 | 2026-08-28 |
| Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma Atezolizumab, Bevacizumab, Biospecimen Collection - Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 63 | 2017-04-25 | 2026-10-14 |
Showing 20 of 51. Sign in to see all of them.
Sarcoma (35) · Histiocytoma, Malignant Fibrous (23) · Neurofibrosarcoma (23) · Sarcoma, Synovial (23) · Leiomyosarcoma (22) · Fibrosarcoma (21) · Liposarcoma (20) · Hemangiosarcoma (18) · Rhabdomyosarcoma (17) · Malignant mesenchymal tumor (14) · Chondrosarcoma, Extraskeletal Myxoid (12) · Hemangiopericytoma, Malignant (12) · Sarcoma, Clear Cell (10) · Dermatofibrosarcoma (7)
Neoplasms (51) · Neoplasms by Histologic Type (51) · Neoplasms, Muscle Tissue (51) · Neoplasms, Connective and Soft Tissue (50) · Neoplasms, Connective Tissue (33) · Neoplasms, Nerve Tissue (27) · Neoplasms, Fibrous Tissue (25) · Nervous System Diseases (25) · Nervous System Neoplasms (25) · Neuromuscular Diseases (24) · Peripheral Nervous System Diseases (24) · Peripheral Nervous System Neoplasms (24) · Neurofibroma (23) · Histiocytoma (22) · Nerve Sheath Neoplasms (22)
Doxorubicin (6) · Ifosfamide (5) · Radiotherapy (4) · Sunitinib (3) · atezolizumab (3) · cediranib (3) · pazopanib (3) · Bevacizumab (2) · Biopsy (2) · Cisplatin (2) · Dacarbazine (2) · Filgrastim (2) · Gemcitabine (2) · Loperamide (2) · Specimen Handling (2)
National Cancer Institute (NCI) (10) · European Organisation for Research and Treatment of Cancer - EORTC (8) · AHS Cancer Control Alberta (2) · Memorial Sloan Kettering Cancer Center (2) · University of Calgary (2) · AEterna Zentaris (1) · Advenchen Laboratories, LLC (1) · Alliance for Clinical Trials in Oncology (1) · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (1) · Canadian Cancer Trials Group (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Children's Oncology Group (1) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · ECOG-ACRIN Cancer Research Group (1)
United States (25) · Canada (12) · United Kingdom (9) · France (6) · Spain (6) · Belgium (5) · Italy (5) · Netherlands (5) · Denmark (4) · Germany (4) · China (3) · Poland (3) · Slovakia (3) · Australia (2) · Austria (2)
Alice P Chen, M.D. (2) · A P Chen (1) · Aaron R Weiss (1) · Alba Rubio (1) · Alice P Chen (1) · Antonio Casado (1) · Axel Le Cesne, MD (1) · Christopher W Ryan (1) · Claudia Valverde (1) · Cristina Mata (1) · Dejka Araujo, MD (1) · Edmund Bartlett, MD (1)
PMID 31401903, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 19088049, PMID 19451429, PMID 20471824, PMID 22605650, PMID 22954508, PMID 23630200, PMID 24215845, PMID 26802156, PMID 28391003, PMID 28950372, PMID 29216400, PMID 29567632, PMID 29669701, PMID 30254189, PMID 30738795, PMID 30954717, PMID 31078463, PMID 31160249, PMID 31502400, PMID 31786124, PMID 32702309, PMID 32827353, PMID 33203665, PMID 33548339, PMID 34392187, PMID 34515544, PMID 34623899, PMID 34722269, PMID 36302173, PMID 36566574, PMID 37523624, PMID 37672694, PMID 38757485, PMID 39122389, PMID 39356980, PMID 41386267, PMID 41836677, PMID 41999612
P30CA008748 (2), U10CA098543 (2), U10CA180886 (2), 2009 (1), 2016 (1), N01CM62206 (1), P30CA012197 (1), P30CA033572 (1), U01CA069856 (1), U10CA081851 (1), U10CA180830 (1), UG1CA189828 (1), ZIABC011078 (1)